Added to YB: 2025-11-10
Pitch date: 2025-11-04
RNA [neutral]
Avidity Biosciences, Inc.
+4.25%
current return
Author Info
BiotechBonanza shares takes on biotech with a heavy focus on special situations. Sign up for the newsletter.
Company Info
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs).
Market Cap
$11.3B
Pitch Price
$68.45
Price Target
72.00 (+1%)
Dividend
N/A
EV/EBITDA
-13.14
P/E
-14.65
EV/Sales
514.55
Sector
Biotechnology
Category
special_situation
3 quick merger arb ideas at >10% yield - Avidity Biosciences, Inc.
RNA (merger arb): Novartis acquiring pre-Phase 3 biotech, guided H1 2026 close. At $69.84 vs $70.3 PV of cash portion = 6.8% annualized return + free SpinCo ($270M cash + BMY/LLY collab rights, est $2-3 value). 99% close probability, no overlap/MAE issues, credible buyer.
Read full article (2 min)